News

These shares were priced at the closing price of $16.44 per share as of September 26, 2008, plus $0.0625 per share, and warrants to purchase an additional 757,461

The launch of Aigisrx implantable cardioverter defibrillator (ICD) is said to extend TyRx’s Aigisrx cardiac rhythm management device (CRMD) platform to the implantable cardioverter defibrillator market. The Aigisrx

The results included sub-analyses conducted to understand how EnteroMedics’s Vbloc vagal blocking therapy affects two co-morbidities frequently associated with obesity: type 2 diabetes and hypertension. Approximately six patients

Using an intelligent traffic light system, Biotronik Home Monitoring quickly and easily identifies patients with the most clinically relevant events to streamline clinic workflow and improve patient care,

The agreement provides Nomad access to Icon’s proprietary technology platforms, including its transient expression technology magnICON, for manufacturing biomaterials and selected biosimilar pharmaceutical proteins in green plants. The

The abbreviated new drug application (ANDA) was submitted to the FDA on August 5, 2008. This is said to be the first application filed by Scolr Pharma with

Approximately 70 women with a history of moderate-to-severe dysmenorrhea participated in this first documented attempt to show prevention of uterine cramping and pain. This double-blind, placebo-controlled clinical trial

Winston will continue as the surviving entity in the merger and as a wholly-owned subsidiary of Getting Ready (GTRY). In connection with the consummation of the merger, GTRY

The multiple ascending dose study is the fourth and final study in the company’s Phase I program for R4996/MEM 63908, a partial agonist of the nicotinic alpha-7 receptor